Tom Wilemon Archive

Jeffrey Rathmell, PhD, directs the Vanderbilt Center for Immunobiology.
July 18, 2019

Center for Immunobiology grows, bolsters program

The Vanderbilt Center for Immunobiology has relaunched its mission with a greater focus on human immunology, an endeavor supported by additional researchers, more funding support and designation as a Center of Excellence.

June 26, 2019

Biomarkers of DNA methylation can be a predictor of breast cancer risk

Biomarkers of DNA methylation, which regulate gene expression, can be a predictor of breast cancer risk.

June 18, 2019

Study identifies critical regulator of tumor-specific T cell differentiation

A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work

June 13, 2019

Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy

More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a multi-institutional study published June 12 in the Journal of Clinical Oncology.

June 13, 2019

Eng named to GI cancer leadership position at VICC

Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, is joining Vanderbilt-Ingram Cancer Center (VICC).

June 13, 2019

Treatment approved for patients with acute graft-versus-host disease

The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC’s Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.